Skip to main content
An official website of the United States government

Oncology Models Forum (OMF)

Image of the Oncology Models Forum

Oncology Models Forum

The Oncology Models Forum (OMF) was launched by the NCI in 2014 to fund research into advancing standard practices for modeling human cancers in mice and to facilitate collaborations, data sharing, and harmonization of mouse models. In 2016, the Funding Opportunity Announcement (FOA) was expanded to all mammalian model systems (PAR-16-059) and has been re-issued in 2017 (PAR-17-245), 2020 (PAR-20-131), and 2023 (PAR-23-281).

Unlike many hypothesis-driven and mechanistic R01 projects, this program is devoted to ensuring mammalian models used for translational research questions are appropriate for those purposes and the models provide reliable and informative data for patient benefit. The OMF now includes a range of models including canine, porcine, organoid, and cell line models, in addition to many diverse mouse model systems.

OMF News and Highlights

OMF Scientist Highlights: Drs. Rosemary Akhurst, Zev Binder, and Ling Cai 

Dr. Rosemary Akhurst is a Professor in the Helen Diller Family Comprehensive Cancer Center at UCSF. Her laboratory studies chemically induced squamous cell carcinomas. In collaboration with Dr. Allan Balmain, a Professor in Cancer Genetics at UCSF, she is undertaking a cross-species investigation into mechanisms the drive the development of drug-resistant tumor cells. Using a model of skin chemical carcinogenesis, this project will explore features of drug resistance to understand how highly heterogenous treatment-resistant cancer cell populations develop and how they can be targeted. 

Dr. Zev Binder is a Research Assistant Professor in the Perelman School of Medicine at the University of Pennsylvania and an NCI MERIT awardee. He combines in vitro and in vivo models of glioblastoma to explore new approaches to therapy. Dr. Binder is also developing a humanized mouse system to study the interactions of the immune system with brain tumors. 

Dr. Ling Cai is an Assistant Professor at UT Southwestern Medical Center. She has built a user-friendly interactive analytical toolset to explore gene expression and clinical data from published datasets. Dr. Cai will further leverage these data to develop an informatics platform enabling comparative analyses to determine the fidelity of preclinical lung cancer models with human patient tumors.  

OMF Funding Opportunity

PAR-24-306: Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)

OMF Meetings

May 16, 2024 
Oncology Models Forum Spring Seminar (Virtual)

December 5-6, 2023
Oncology Models Forum Annual Meeting 

July 23, 2023 
Oncology Models Forum Summer Seminar

March 15-16, 2022 
Oncology Models Forum Annual Meeting

December 9, 2021
Oncology Models Forum Fall Seminar

July 27, 2021
Oncology Models Forum Summer Seminar

March 30-31, 2021
Oncology Models Forum Annual Meeting (Virtual) 

January 30, 2020
NCI Oncology Models Forum Meeting (NCI Shady Grove)

November 8, 2018
NCI Oncology Models Forum Meeting (University of California, San Francisco)

September 18-19, 2017
Immune Interventions in Oncology: A Think Tank on Modeling Opportunities using Mice and Human Specimens (NCI Shady Grove)

NCI and OMF Resources Related to Oncology Models

  • Cancer Tissue Engineering Collaborative (TEC) – supports the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. 
  • Human Cancer Models Initiative (HCMI) Catalog – Resource of patient-derived next-generation cancer models developed by HCMI, which is an international collaboration between NCI, Cancer Research UK, the Wellcome Sanger Institute, and Hubrecht Organoid Technology
  • NCI Mouse Repository NCI-funded resource for mouse cancer models and associated strains
  • Oncology Model Fidelity Score – Uses the Hallmarks of Cancer to compare cancer animal models to human cancer
  • Single R – Analyzes cellular heterogeneity from single-cell RNA sequencing data
  • Xcell – Analyzes cellular heterogeneity from bulk gene expression data

Contacts for the OMF

For additional information about the OMF, please contact Dr. Joanna Watson or Dr. Christine Nadeau

Funded Projects

InstitutionPrincipal Investigator(s)Project Title
Baylor College of MedicineYong LiOptimizing syngeneic mouse models to target mutant p53
Baylor College of MedicineLanlan ShenEpigenetically engineered mouse model for lung cancer therapy
Baylor College of MedicineXiang Zhang, Yi LiNext generation rat models of ER+ breast cancer
Beth Israel Deaconess Medical CenterVassiliki A. Boussiotis, Alain Charest, Roel VerhaakUnderstanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments
Brigham and Women's HospitalDerin B. Keskin, Christopher A. French, Geoffrey I. ShapiroGenetically engineered mouse model to improve therapy of NUT carcinoma
Cedars Sinai Medical CenterJlenia GuarnerioComparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilities
Cincinnati Children's Hospital Medical CenterStephanie Halene, H. Leighton GrimesModeling myelodysplasia
Cleveland Clinic Lerner College of MedicineJianjun ZhaoNew mouse model of cisplatin-induced AKI and development of prevention therapy
Dana-Farber Cancer InstituteKevin HaigisMouse models of Kras-mutant colorectal cancer
Duke UniversityMing ChenEngineering large chromosomal deletions in mice to advance precision oncology
Duke UniversityJoshua C. SnyderVisualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancer
Emory UniversityPeter Canoll, Nicholas M. BoulisLentiviral-induced swine model of spinal cord glioma
Jackson LaboratoryVishnu HosurSite-specific integration of large (10-100 kb) DNA constructs into the mouse genome and human induced pluripotent stem cells using the Cas9-Bxb1 integrase toolbox
Johns Hopkins UniversityRichard B. Roden, Chien-Fu HungMouse modeling of HPV infection
Massachusetts Institute of TechnologyJesse S. BoehmRapid ex vivo biosensor cultures to assess dependencies in gastroesophageal cancer
Mayo Clinic, ScottsdaleMarta Chesi, Peter L. BergsagelPreclinical optimization of BCMA directed T cell therapy
MD Anderson Cancer CenterGiannicola GenoveseInvestigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma
MD Anderson Cancer CenterFrederick F. LangA novel adenoviral-permissive, immunocompetent hamster model to evaluate oncolytic adenoviral therapy for glioblastoma
Memorial Sloan-Kettering Cancer CenterScott W. LoweRapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies
Memorial Sloan-Kettering Cancer CenterJesse J. SmithExpansion of tumoroid models for precise treatment of the rectal cancer patient
Northwestern UniversityDaniel J. BratModeling the glioblastoma microenvironment to uncover progression mechanisms and therapeutic targets
Rockefeller UniversityStylianos BournazosNovel transgenic mouse models addressing outstanding translational barriers in antibody-based therapeutics
Roswell Park Comprehensive Cancer CenterMukund SeshadriRadiogenomic credentialing of head and neck cancer models
Tufts Medical CenterIris Z. Jaffe, Cheryl A. LondonCredentialing a cross-species platform to investigate cancer therapy-associated cardiovascular toxicity
University of Alabama, BirminghamRobert A. Kesterson, Deeann Wallis SchultzLoss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system
University of Alabama, BirminghamDonald M. O'Rourke, Christopher R. Miller, Frank FurnariCredentialing next-generation human glioma models for precision therapeutics
University of California, DavisRobert B. RebhunClinical, molecular, and immune characterization of naturally occurring osteosarcoma in dogs
University of California, Los AngelesAnthony P. HeaneyDevelopment of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
University of California, San DiegoMichael KarinA new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
University of California, San DiegoMichael KarinHighly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors
University of California, San FranciscoAllan Balmain, Rosemary J. AkhurstA network approach to interrogate cellular plasticity and drug resistance in cancer
University of California, San FranciscoNalin GuptaMyeloid cells and radiation-induced memory deficits in rodent glioma model: sex and age effects
University of California, San FranciscoEric Alejandro Sweet Cordero, Olena Morozova VaskeDevelopment of advanced preclinical models for pediatric solid tumors
University of Colorado DenverPatricia Ernst, Terry J. FryEscape from CAR T surveillance through lineage plasticity
University of GeorgiaWilliam Hildebrand, Shaying ZhaoCanine MHC-I genotyping and tumor specific neoantigen determination
University of Massachusetts Medical School WorcesterElinor Karlsson, Cheryl A. LondonLeveraging canine spontaneous cancer to optimize the power of blood biopsy
University of Massachusetts Medical School WorcesterWen XueIn vivo prime editing for precision cancer mouse models
University of PennsylvaniaZev Ari BinderDevelopment and validation of an autologous mouse model for the study of immune interactions with glioblastoma
University of PennsylvaniaXiaowei Xu, Meenhard F. HerlynGamma delta T cell based melanoma therapies
University of PittsburghSteffi Oesterreich, Adrian V. LeeCredentialing models of invasive lobular breast cancer for translational research
University of Wisconsin, MadisonRandall J. KimpleImproving the translational value of head and neck cancer patient-in-mouse models
University of Texas Southwestern Medical CenterLing Cai, Shidan WangConstruction of a lung cancer preclinical model cross-comparison platform
University of Texas Southwestern Medical CenterDiego H. CastrillonPolymerase epsilon-based mouse and derived organoid models of intestinal cancer
University of Texas Southwestern Medical CenterDiego H. CastrillonPolymerase-mediated ultramutagenesis and carcinogenesis in mice
University of Texas Southwestern Medical CenterHao ZhuImproving hepatocellular carcinoma mouse modeling by understanding the malignant potential and biology of liver cell subpopulations
Washington University in St. LouisRichard A. Flavell, Ryan C. FieldsAdvancing precision oncology in a humanized, fully autologous mouse model
Washington University in St. LouisJeffrey A. Magee, Jeffery M. KlcoCross-species development and credentialing of pediatric AML models
Wayne State University Jennifer B. Jacob, Benjamin L. KidderDefining cancer intervention targets by functional genomics analysis of outbred F1 mice
Weill Cornell MedicineLukas E. DowIn vivo base editing for precision oncology models
Weill Cornell MedicineTan A. InceCulture of tumor versus normal cells
Weill Cornell MedicineDawid G. NowakNovel mouse models for quantitative understanding of baseline and therapy-driven evolution of prostate cancer metastasis
Yale UniversityNikhil JoshiDeveloping translationally-relevant genetically engineered mouse models of lung adenocarcinoma for investigations in cancer immunology
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Oncology Models Forum (OMF) was originally published by the National Cancer Institute.”

Email